[Melfalan in the treatment of proliferative vitreoretinopathy (experimental study)].

Purpose: To study of the effectiveness of the drug Melphalan as an antiproliferative agent during experimental proliferative vitreoretinopathy (PVR).

Material And Methods: The experimental study used data from 24 eyes of 12 Chinchilla rabbits weighing 2.5-3.0 kg, which had PVR modeled in both eyes by intravitreal injection of a culture of heterogeneous activated fibroblast cells consisting of 200,000 cells in 0.1 ml. Treatment of experimental PVR was performed 1 day after the modeling process. In the first group of animals (6 eyes), 0.02 mg of Melphalan was administered intravitreally. In the second group of animals (6 eyes), 0.005 mg of Melphalan concentrated in 0.1 ml was administered intravitreally. Left eyes in both groups remained without treatment. Animals were observed for 1 month using biomicroscopy and ophthalmoscopy. 30 days after the animals were removed from the experiment, the eyes were enucleated, fixed in 10% buffered formalin and subjected to standard histological examination. The study of paraffin sections of the eyes was performed using the microscopic system «Leica» (Leica Microsystems, Germany) with built-in digital camera at the magnification of 200-600.

Results: In groups 1 and 2 of the study in the eyes of rabbits that received treatment, PVR was absent, unlike the eyes without treatment, where PVR remained. In group 1, where the dose of Melphalan was 0.02 mg in 0.1 ml, there were changes in the RPE (retinal pigment epithelium), which was regarded as a retinotoxic effect. Glial degeneration and thinning of the retina with disappearance of the photoreceptor layer (the outer nuclear and plexiform layers) resulted from the disturbance of retinal metabolism caused by RPE destruction. In group 2, structure of the retina remained more intact: isolated foci were noted with a decrease in the volume of the outer nuclear layer, shortening of rods and cones with preservation of the inner layers of the retina.

Conclusion: A single intravitreal injection of 0.005 mg Melphalan had a positive therapeutic antiproliferative effect on the PVR model with minimal retinotoxic changes.